Learning Objective: Mitigate TRAEs and toxicities with bsAbs to improve tolerability and maintain quality of life (QoL) for patients with RRMM
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
AMA PRA Category 1 Credit™Up to 1 creditNursingUp to 1 creditPharmacyUp to 1 credit
MOC types
No MOC
FDA REMS
No
Qualifies for MIPS
No
Target Specialties
Address:
- 40946 US Highway 19 N
Pricing
CME included with membership · $19.99/mo
| Regular Membership | Free |
| Affiliated Health Professional Membership | Free |
| MENASA Group Explorer | Free |
| MENASA Group Elite Member | $19.99/mo |
Collected from the provider’s public pages · source
Specialties served/covered
- Cardiovascular Disease
- Clinician Wellness & Burnout
- Communication & Shared Decision-Making
- Diagnostic Radiology
- Emergency Medicine
- Endocrinology, Diabetes & Metabolism
- Evidence-Based Medicine & Research
- Family Medicine
- Gastroenterology
- General Internal Medicine
- General Pediatrics
- Geriatric Medicine
- Health Equity & Inclusion
- Hematology
- Hospice & Palliative Medicine
- Medical Oncology
- Metabolic & Bariatric Surgery
- Nephrology
- Neurology
- Neuroradiology
- Ophthalmology
- Patient Education & Health Literacy
- Pediatric Gastroenterology
- Practice Management & Ethics
- Pulmonary Disease
- Sleep Medicine
- Thoracic Surgery
- Cardio-Vascular
- Cross-Specialty
- Emergency & Critical Care
- GI & Liver
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Neurology
- Oncology & Hematology
- Pain & Palliative
- Pediatrics
- Primary care
- Radiology
- Surgery
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- On-demand / recorded video
- Credit · Up to 1 credit
- Commercial Support
-
ReleasedFeb 10, 2026
-
Last day to claim creditFeb 10, 2027 4 months left
-
Society of Hematologic Oncology +1 Optimizing Treatment Approaches and Clinical Practice for Relapsed/Refractory Multiple Myeloma
-
The Society of Hematologic Oncology +1 Optimizing Treatment Approaches and Clinical Practice for Relapsed/Refractory Multiple Myeloma | Evolving Role of Bispecific Antibody Therapy in the Treatment Landscape for RRMM
-
The Society of Hematologic Oncology +1 Optimizing Treatment Approaches and Clinical Practice for Relapsed/Refractory Multiple Myeloma | Leading the Advancement of Health Equity in MM
-
Clinical Care Options, LLC (dba Decera Clinical Education) Managing Bispecific Antibody-Related Toxicities in Your Patients With Multiple Myeloma: Interdisciplinary Guidance and Care Coordination for Community HCPs
-
University of Chicago School of Medicine Sustainable and Scalable Strategies for Safe and Effective Administration of Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma in Outpatient and Community Settings
-
Efficient CME, CME Outfitters, LLC From Trial to Treatment: Using Modern Evidence, Expert Insight, and Practice Simulation to Navigate the Integration of Bispecific Antibodies into the Care of Patients with Multiple Myeloma
